This study evaluated XPc's protective effects in vivo using Aβ<sub>25-35</sub>-treated mice, a pharmacological AD model, and explores its synergistic potential with neuroprotective agents like TSPO activators or sigma-1 receptor agonists. This evidence concerns the gene TSPO and Alzheimer disease.